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Abstract Introduction: No licensed medications are available to treat vascular dementia (VaD).
Methods: Patients were randomly assigned to experimental groups (SaiLuoTong [SLT] 360 or
240 mg for groups A and B for 52 weeks, respectively) or placebo group (SLT 360 mg and
240 mg for group C only from weeks 27 to 52, respectively).
Results: Three hundred twenty-five patients were included in final analysis. At week 26, the differ-
ence in VaD Assessment Scale–cognitive subscale scores was 2.67 (95% confidence interval, 1.54 to
3.81) for groups Aversus C, and 2.48 (1.34 to 3.62) for groups B versus C (both P, .0001). However,
at week 52, no difference was observed among the groups on the VaD Assessment Scale–cognitive
subscale (P 5 .062) because of the emerging efficacy of SLT in placebo beginning at week 27.
Discussion: This study suggests that SLT is effective for treatment of VaD, and this compound Chi-
nese medicine may represent a better choice to treat VaD.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Background
Vascular dementia (VaD) is a cognitive dysfunction syn-
drome caused by ischemic stroke, hemorrhagic stroke, and
cerebral vascular disease [1]. In China, the prevalence of
VaD is 1.50% [2], and it is estimated that there are approxi-
mately three million patients with this disease [2,3].
Although acetylcholinesterase inhibitors, such as
donepezil, galantamine, and rivastigmine, showed positive
therapeutic effects on VaD in clinical trials, there are still
no licensed medications that meet the criteria of the US
Food and Drug Administration or the European Medicine
Agency for this disease [1]. This requires that the drugs
should show global or functional benefits, in addition to
cognitive benefits, for approval [4,5]. In recent years, an
increasing number of clinical trials have been conducted to
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test the effects of compound Chinese medicines for treating
VaD, and many have shown positive effects by improving
cognitive or behavioral symptoms [6].
The SaiLuoTong (SLT) capsule is a modern compound
Chinese medicine that is manufactured by Shineway Phar-
maceutical Group Co., Ltd (Shijiazhuang, China). It con-
sists of active ingredients quantified in milligrams (for
details, see eTable 1 in Supplementary 2) and derived
from Ginkgo biloba, ginsenosides, and saffron in a 5:5:1
proportion per capsule, based on preclinical studies.
Ginkgo biloba has antiinflammatory properties [7] and
stimulates hippocampal neurogenesis [8]. Ginsenoside
Rg1 inhibits oxidative stress-induced neuronal apoptosis
[9], protects against neurodegeneration in cultured hippo-
campal neurons [10], and improves memory function in
Alzheimer’s disease (AD) and estrogen-deficient rat
models [11,12]. Saffron has the capacity to scavenge
oxygen free radicals [13], improve learning and memory
in animal models of chronic stress [14], and alleviate
neuronal injury in vitro and in vivo [15]. It also moderately
inhibits acetylcholinesterase, which is the main effect of
donepezil in AD [16], and a clinical trial showed that
saffron has similar cognitive-enhancing effects to donepezil
in patients with AD [16]. All of these functions of Ginkgo
biloba, ginsenosides, and saffron in SLT are related to po-
tential mechanisms that could help treat VaD.
Therefore, we hypothesized that SLT may have therapeu-
tic efficacy in patients with mild-to-moderate VaD and de-
signed the present clinical trial to test this.
2. Methods
2.1. Study design and participants
This 59-week, phase II, randomized, controlled, double-
blind, parallel-arm study was performed at 16 academic cen-
ters throughout China. A protocol amendment was made on
April 27, 2013, which increased the follow-up period from
61 week to 62 weeks for each visit to reduce the dropout
rate. Fig. 1 displays an overall schematic of the design.
Eligible patients had to be aged 40 years, male or fe-
male, Han Chinese, have5 years of education, have a diag-
nosis of probable VaD of mild to moderate severity, and have
evidence of ischemic lesions on brain magnetic resonance
imaging. Exclusion criteria were non-VaD primary dementia
or non-ischemic VaD, disturbances of consciousness, severe
aphasia, physical disabilities, or any other factor that could
preclude the completion of neuropsychological testing.
The full details of the inclusion and exclusion criteria are
provided in eAppendix 1 in Supplementary 2.
The study protocol (Supplementary 1) was approved by
independent ethics committees at all study sites. Written
informed consent was obtained from each patient, or from
the patient’s legal guardian or representative, before enroll-
ment. This study was registered at ClinicalTrials.gov
(NCT01978730).
2.2. Randomization and masking
Randomization was performed using an interactive web
response system and stratified according to severity of VaD
(two levels: mild and moderate) and center (16 centers in
total). Interactive web response system generated the
randomization sequence with 33 blocks ! 12 (4:4:2:2).
The patient randomization file consisted of the trial
randomization number and treatment group code. A drug
kit number list was generated and subsequently assigned
to the patients by interactive web response system. The
personnel involved in the execution and data analysis
were blinded to the drug kit randomization list. Study par-
ticipants, their caregivers, and all assessors remained
blinded to the treatment assignments throughout the study,
and safety assessors were not permitted to be involved in
the primary efficacy assessments. The SLT and placebo
were identical in appearance, smell, and taste, to maintain
blinding.
2.3. Study intervention
The trial began with a 1-week screening period and a 4-
week placebo run-in period, and participants were randomly
assigned to four groups: group A, SLT 360 mg, and group B,
240 mg SLT, for 52 weeks; group C (C1 and C2), placebo for
the first 26 weeks and switched to SLT 360 mg and 240 mg,
respectively, for the next 26 weeks (Fig. 1). Treatment
compliance was monitored by counting the capsules. The
number of capsules taken was recorded in a diary and re-
viewed at each clinic visit.
2.4. Primary and second outcomes
The coprimary outcomes included the Vascular De-
mentia Assessment Scale–cognitive subscale (VaDAS-
cog) [17] and Alzheimer’s Disease Cooperative Study–
Clinical Global Impression of Change (ADCS-CGIC)
scores [18]. The VaDAS-cog is composed of 14 items
related to memory and orientation, language, the ability
to practice, attention focus, and executive function
(score ranges from 0 [no impairment] to 90 [serious
impairment]). The ADCS-CGIC is a version of the clini-
cian’s interview-based impression of change plus care-
giver input [19,20] and covers four domains (general,
mental cognitive state, activities of daily living
[ADLs], and behavior), with scores ranging from 1
(significant improvement) to 7 (severe deterioration).
An experienced clinician performed the ADCS-CGIC
and was blinded to all of the other psychometric assess-
ments. The secondary outcomes included the Mini–
Metal State Examination (MMSE), ADCS-ADLs, and
Clinical Dementia Rating (CDR) scale scores, perfor-
mance on the clock drawing task (CLOX) and the Chi-
nese version of the executive interview (C-EXIT25),
and the Neuropsychiatric Inventory (NPI). These scales
evaluate global cognition, living ability, dementia
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severity, executive function, mental status, and behavior.
The patients were assessed at baseline and at weeks 13,
26, 39, and 52 with respect to the VaDAS-cog and
ADCS-CGIC, and at baseline and weeks 26 and 52 for
the MMSE, CDR, ADCS-ADLs [21], CLOX [22], C-
EXIT25 [23], and NPI [24]. Brain magnetic resonance
imaging scans were performed at baseline and at
week 52.
randomized
analyzed analyzed analyzed
Fig. 1. Trial profile. Abbreviations: AE, adverse event; SAE, serious adverse event; mITT, modified intent to treat.
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2.5. Evaluation of safety
We monitored patients throughout the study for adverse
events (AEs), serious adverse events (SAEs), and concomi-
tant medication use and performed clinical and laboratory
examinations including measurements of vital signs, phys-
ical and neurological examinations, and 12-lead electrocar-
diography at all clinical visits (screening, baseline, and
weeks 13, 26, 39, 52, and 54).
2.6. Statistical analysis
The power of this study was calculated based on the
change in primary endpoint from baseline on the VaDAS-
cog. Because the clinical use of SLT in patients with
VaD is still in the exploratory stages and no previous trial
results are available, the result of a clinical trial of meman-
tine in patients with VaD was used as a reference to calcu-
late sample size, in which the drug-placebo difference in
change from baseline on the ADAS-cog was 2.83 (SD
5.72) [25]. The two-sided t-test with a significance level
of 5% was used. As a result, 86 patients were needed per
group to achieve 90% power. Given an expected dropout
rate of 20%, the total number of patients to be randomized
was 324.
The primary and secondary outcomes were analyzed
using data from the modified intent-to-treat (mITT) pop-
ulation. In this study, the mITT population consisted of
all randomly assigned patients who took at least one
dose of the study medication and had both a baseline
and (at least one) postbaseline efficacy assessment.
Missing values for the primary endpoint measures were
replaced using the last observation carried forward
method. No missing data were imputed for the secondary
endpoint measures.
The statistical analysis plan was finalized, and the data-
base was locked in September 2016. The comparison of
VaDAS-cog scores within groups, at baseline and at weeks
13, 26, 39, and 52, was done using the paired t-test. For
the first phase (weeks 0–26), the changes from baseline in
VaDAS-cog and ADCS-CGIC scores, at weeks 13 and 26,
were analyzed using analysis of covariance, with groups as
a fixed effect, center as a random effect, and the baseline
score and degree of disease as covariates. For the second
phase (weeks 27–52), changes in coprimary outcomes
from baseline and at weeks 39 and 52 were analyzed using
the same model. The ADCS-CGIC scores were analyzed
as categorical data using the Cochran-Mantel-Haenszel
method.
For secondary outcomes, such as the MMSE, CDR, C-
EXIT25, CLOX, ADCS-ADLs, and NPI, the paired t-test
or the Mann-Whitney U test was used to compare scores
before and after treatment within groups. One-way anal-
ysis of variance or the Kruskal-Wallis test was conducted
to compare the changes at weeks 26 and 52 from base-
line between the groups. The safety set consisted of all
subjects who took at least one dose of the study medica-
tion and had at least one postbaseline safety evaluation.
The incidence of AEs at weeks 26 and 52 was compared
between the groups using the c2 test or Fisher’s exact
test.
All analyses were conducted using SAS software
(ver. 9.4; SAS Institute, Cary, NC, USA). All hypothesis
tests were two-tailed, and P values  0.05 were considered
significant. All data were overseen by a Data and Safety
Monitoring Board.
3. Results
3.1. Study participants
We screened 388 patients from March 28, 2013 to
February 25, 2014; the last patient withdrew from the trial
on April 21, 2015. Of the 340 patients randomly assigned
to treatment, 114 cases (94 finished this study, 82.5%) were
in the high-dose group (group A, 180 mg, twice daily), 113
(100, 88.5%) were in the low-dose group (group B,
120 mg, twice daily), and 113 (98, 86.7%) were in the con-
trol group C (57 in C1 and 56 in C2). Causes of dropout
were withdrawal, loss to follow-up, and AEs. In total,
325 patients (109 cases in group A, 108 cases in group
B, 55 cases in group C1, and 53 cases in group C2)
received at least one dose of the study drug with a safety
assessment and comprised the safety set or received at least
one postbaseline efficacy assessment and comprised the
mITT population (Fig. 1). The baseline demographic and
clinical characteristics of the mITT population are shown
in Table 1.
3.2. Coprimary endpoints
The changes in the least squares mean scores between
week 26 and baseline on the VaDAS-cog were 23.25
(standard error [SE] 0.45) for group A, 23.05 (0.45) for
group B (both P , .0001), and 20.57 (0.45) for group C
(P 5 .15), with a significant difference among groups
(P, .0001) (Fig. 2A). The differences were 2.67 (95% con-
fidence interval, 1.54–3.81) between groups A and C, and
2.48 (1.34–3.62) between groups B and C (both
P , .0001). However, the difference between groups A
and B was not significant [0.20 (20.94 to 1.34), P 5 .73],
indicating that they had similar effectiveness. On week 52,
the VaDAS-cog scores changed from baseline, by 24.88
(SE 0.61) in group A, 24.93 (0.62) in group B, 22.68
(0.82) in group C1 and 23.50 (0.84) in group C2
(P , .0001 for groups A, B, and C2; P 5 .00070 for group
C1), with no significant difference among the four groups
(P 5 .062) (Fig. 2A). For the ADCS-CGIC, at week 26,
the change in the least squares mean score was 3.57 (SE
0.10) for group A, 3.57 (0.10) for group B, and 3.88
(0.10) for group C, with a significant difference among
groups (P 5 .028): groups A and B were more effective
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than group C [C1 and C2 were combined for the first
26 weeks, i.e., 0.31 (0.05–0.57), P 5 .028, between groups
A and C and 0.31 (0.05 to 0.57), P5 .019, between groups B
and C]. At week 52, the change in the least squares mean
score from baseline was 3.36 (SE 0.12) for group A, 3.33
(0.12) for group B, 3.55 (0.16) for group C1, and 3.58
(0.17) for group C2, with no significant difference among
the four groups (P 5 .45) (Fig. 2B), suggesting that the
Table 1
Characteristics of the treatment group at baseline
Characteristic Group A (n 5 109) Group B (n 5 108) Group C (n 5 108) P
Age, mean (SD), y 64.9 (9.1) 66.0 (9.2) 66.0 (9.3) .5871
Education distribution, n (%) .4380
41–50 5 (4.6) 5 (4.6) 4 (3.7)
51–60 34 (31.2) 33 (30.6) 32 (29.6)
61–70 45 (41.23) 30 (27.8) 35 (32.4)
71–80 20 (18.6) 35 (32.4) 30 (27.8)
81–90 5 (4.6) 5 (4.6) 7 (6.5)
Female, n (%) 42 (38.5) 39 (36.1) 29 (26.9) .1591
Education, mean (SD), y 9.9 (3.4) 9.6 (3.5) 9.8 (3.5) .7823
Education distribution, n (%) .8478
Primary school 29 (26.9) 26 (23.9) 28 (25.9)
Middle school 32 (29.6) 32 (29.3) 33 (30.6)
High school 32 (29.6) 34 (31.2) 29 (26.9)
College 15 (13.9) 17 (15.6) 18 (16.7)
Medical history, n (%)
Hypertension 93 (85.3) 94 (87.0) 87 (80.6) .3981
Hyperlipidemia 16 (14.7) 10 (9.3) 14 (13.0) .4628
Diabetes mellitus 52 (47.7) 39 (36.1) 52 (48.2) .1294
Atrial fibrillation 2 (1.8) 0 (0.0) 3 (2.8) .0977
Coronary heart disease 15 (13.8) 13 (12.0) 16 (14.8) .8340
Lung disease 8 (7.3) 5 (4.6) 8 (7.4) .6381
Gastrointestinal disease 25 (22.9) 35 (32.4) 28 (25.9) .2762
Stroke 109 (100.0) 108 (100.0) 108 (100.0) .4924
Large-artery atherosclerosis 37 (33.9) 30 (27.8) 32 (29.6)
Cardioembolism 2 (1.8) 0 (0.0) 0 (0.0)
Small-artery occlusion lacunar 63 (57.8) 73 (67.6) 68 (63.0)
Acute stroke of other determined etiology 2 (1.8) 3 (2.8) 4 (3.7)
Stroke of other undetermined etiology 5 (4.6) 2 (1.9) 4 (3.7)
Personal history, n (%)
Alcohol intake 37 (33.9) 39 (36.1) 47 (43.5) .3134
Smoking 45 (41.3) 45 (41.7) 49 (45.4) .7984
Concomitant drugs in at least 10 patients, n (%) 98 (89.9) 94 (87.0) 94 (87.0) .7535
Calcium channel blocker agents 43 (39.5) 48 (44.4) 46 (42.6) .7634
Lipid regulator agents 27 (24.8) 23 (21.3) 24 (22.2) .8415
Renin angiotensin system agents 32 (29.4) 18 (16.7) 19 (17.6) .0465
Analgesics 47 (43.1) 38 (35.2) 40 (37.0) .4628
Antidiabetic agents 35 (32.1) 23 (21.3) 30 (27.8) .1859
Other Chinese medicine 14 (12.8) 14 (13.0) 14 (13.0) 1.0000
Psychometric scores, mean (SD)
VaDAS-cog 31.5 (10.1) 30.8 (9.5) 31.8 (9.9) .7611
MMSE 19.9 (3.4) 19.7 (3.7) 19.8 (3.6) .8377
CDR 1.4 (0.5) 1.4 (0.5) 1.4 (0.5) .7984
CDR-SB 6.6 (2.4) 6.5 (2.4) 6.5 (2.4) .9839
ADCS-ADLs 50.0 (11.6) 51.5 (11.1) 50.8 (9.4) .5889
CLOX 10.1 (3.4) 10.2 (3.0) 10.2 (2.9) .9755
C-EXIT25 18.3 (7.7) 17.9 (7.6) 17.7 (6.8) .8341
NPI for patients 5.9 (5.4) 5.5 (4.6) 5.7 (4.9) .8174
NPI for caregivers 3.1 (3.4) 2.8 (3.1) 2.8 (3.4) .7966
HAMD 6.7 (3.7) 6.2 (3.2) 6.0 (3.7) .2630
mHIS 9.5 (1.2) 9.6 (1.4) 9.7 (1.3) .7675
Abbreviations: SD, standard deviation; VaDAS-cog, Vascular Dementia Assessment Scale–cognitive subscale; MMSE, Mini–Mental State Examination;
CLOX, clock drawing task; C-EXIT25, Chinese version of the executive interview; NPI, Neuropsychiatric Inventory; CDR, Clinical Dementia Rating;
CDR-SB, the sum of boxes of the CDR; ADCS-ADLs, Alzheimer’s disease cooperative study activities of daily living; HAMD, Hamilton Depression Scale;
mHIS, Modified Hachinski Ischemic Scale.
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effect of SLT in the control group was close to that in the
active groups.
3.3. Secondary endpoints
MMSE scores increased from baseline by 1.856 1.29 in
group A, 1.816 1.55 in group B and 0.376 2.53 in group C
at week 26 (P, .0001 for groups A and B; P5 .15 for group
C), with a significant difference among the groups
(P , .0001). At week 52, MMSE scores increased signifi-
cantly and were 2.35 6 2.63 for group C1, and
2.09 6 1.52 for group C2 (both P , .0001) after using
SLT. The CDR, CDR-sum of boxes, CLOX, C-EXIT25,
and ADCS-ADLs produced results similar to those of the
MMSE, supporting the positive results of the primary out-
comes (Table 2). The change in the NPI score from baseline
was significantly different within groups A and B, but not
among all groups at week 26 (P 5 .35) or 52 (P 5 .84)
(Table 2). The details of the results for all outcomes are listed
in eAppendix 2 in Supplementary 2.
3.4. Safety
In total, 287 patients (88.3%) experienced at least one
AE at week 26: group A, 91 (83.5%); group B, 101
(93.5%); and group C, 95 (88.0%). No significant differ-
ence was seen among the three groups (P 5 .066)
(Table 3). At week 52, 247 patients (76.0%) experienced
at least one AE: group A, 81 (74.3%); group B, 80
(74.1%); and group C1, 44 (80.0%), and group C2, 42
(79.3%), with no significant difference among the four
groups (P 5 .78) (Table 3). Among all of the AEs, 43 cases
were judged by the investigators to be related to SLT, with
symptoms including mild gastrointestinal intolerance (two
in group A, one in group B, and two in group C), abnormal
alanine aminotransferase (six in group A, one in group B,
and two in group C), abnormal aspartate aminotransferase
(three in group A), increased thrombin time (eight in group
A, three in group B, and four in group C), and dreaminess
(one in group A, three in group B, and seven in group C).
SAEs occurred in eight subjects, including five cerebral in-
farctions (three in group A and two in group C), one with
acute coronary syndrome in group A, one with acute bron-
chitis in group B, and one with lung cancer in group A,
which were deemed by the investigator to be being unre-
lated to the study medication. Details are provided in
Table 3.
4. Discussion
Our findings suggest that SLT improved cognition and
daily functioning in Chinese patients with mild-to-
moderate VaD. The scores on the VaDAS-cog and
ADCS-CGIC in the active groups were significantly supe-
rior at week 26 compared to those of the control group. At
week 52, the benefits seen over the first 26 weeks in
groups A and B were reproduced in the second 26 weeks
in control groups C (C1 and C2) after using SLT. These
results indicate that SLT can improve functioning in mul-
tiple domains, such as memory, orientation, language and
executive function. The changes from baseline in the
active groups were significant at weeks 26 and 52 for
scores on the MMSE, CDR, ADCS-ADLs, CLOX, and
C-EXIT25, indicating that SLT significantly enhanced
global cognitive function, particularly executive function
and ADLs. Taken together, most of the primary and sec-
ondary outcomes were consistent in supporting the poten-
tial efficacy of SLT for VaD, particularly in confirming
efficacy in the control subjects, who were switched to an
active dose during the second 26 weeks. The results
Fig. 2. Changes in the VaDAS-cog and ADCS-CGIC scores from base-
line to weeks 26 and 52 among the different groups. (A) The change in
the VaDAS-cog score from baseline among groups was significantly
different (P , .0001) at week 26. No significant difference was seen at
week 52 (P , .062), confirming similar efficacy between the active and
control groups after using SLT in the second 26 weeks of the study.
(B) The change in the ADCS-CGIC score from baseline among groups
was significantly different (P 5 .028) at week 26. Efficacy appears in
groups C1 and C2 following use of SLT at week 52. Error bars are
95% confidence intervals. P represents the significance of the difference
among groups. Abbreviations: VaDAS-cog, Vascular Dementia Assess-
ment Scale–cognitive subscale; ADCS-CGIC, Alzheimer’s Disease
Cooperative Study–Clinical Global Impression of Change; LSM, least
squares mean; SLT, SaiLuoTong.
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were reproduced in the second cohort within the same trial
under the same conditions, which lends added credence to
the findings.
The VaD disease mechanisms are complex and mixed.
In general, the major pathogenesis of VaD has been attrib-
uted to (chronic or acute) global or local hypoperfusion and
thromboembolic events, oxidative stress, and the inflamma-
tory response [26]. In recent years, Chinese medicine in-
gredients have been combined in complex formulations
to treat cognitive disorders. Researchers have argued that
the reason for the efficacy of modern compound Chinese
medicines is that the bioactive components interact syner-
gistically leading to greater pharmacological effects or bet-
ter clinical outcomes than predicted by the activity of
single components [27]. As all of the active ingredients
in Ginkgo biloba, ginsenosides, and saffron in the SLT
have potential efficacy against the complex disease path-
ways underlying VaD, their combination was considered
to have the potential to maximize the effects. Because
SLT has useful effects on hypoperfusion, inflammatory
changes, oxidative stress, cholinergic system dysfunction,
calcium overload, apoptosis and platelet aggregation, we
assume it has multiple potential targets. The multiple ef-
fects might represent a particular advantage of SLT with
multiple ingredients. Although the present findings suggest
that SLT may be beneficial, a further rigorous controlled
study is required.
No significant differences were observed in the fre-
quency of most common AEs among the active groups
and control, but we could not ascertain an association
between SLT usage and these abnormal laboratory re-
sults. This may be due to our elderly participants, who
had many comorbidities, such as diabetes, high blood
pressure, hyperlipidemia, and other common diseases.
Among the AEs, the symptoms we considered possibly
related to SLT were head discomfort, insomnia,
decreased appetite, dizziness and abnormal coagulation.
No satisfactory explanation has been given for these
symptoms. The SAEs were not different between the
SLT and placebo groups, or between the high- and low-
dose groups. All SAEs were considered unrelated to the
study drug. In general, we conclude that SLT may be
safe and tolerable for the treatment of mild-to-moderate
VaD.
This study had limitations and strengths. Because pre-
clinical studies showed that SLT had the ability to in-
crease cerebral perfusion, reduce the inflammation
cascade and inhibit acetylcholinesterase, it may be neces-
sary to measure these pathophysiological changes in vivo
during a clinical trial. If such changes can be matched
with the psychometric outcomes, it would help to provide
objective support for the multiple potential mechanisms of
action of SLT. A strength of our study was the two-stage
efficacy evaluation. The exploratory phase during the first
26 weeks was designed to test whether SLT was effective,
and the repetition phase during the second 26 weeks was
designed to retest whether the effectiveness obtained dur-
ing the first 26 weeks could be repeated in the second
26 weeks in a cohort originally randomized to receive
the placebo. Although the second phase lacked a corre-
sponding control, the similarity of the changes seen dur-
ing the second phase provided support for the findings
seen in the first phase.
In conclusion, our results demonstrate that SLT may be
safe and effective for treating mild to moderate VaD. This
study suggests that a modern compound Chinese medicine
Table 2
Scores of the primary and secondary outcomes at weeks 26 and 52 in the mITT population
Week 26 Week 52
Mean (SD) change from baseline Mean (SD) change from baseline
Psychometric scores
Group A
(n 5 109)
Group B
(n 5 108)
Group C
(n 5 108)
P value
(among
groups)
Group A
(n 5 109)
Group B
(n 5 108)
Group C1
(n 5 55)
Group C2
(n 5 53)
P value
(among
groups)
Primary outcomes
VaDAS-cog 23.26 6 4.30 23.06 6 4.88 20.53 6 3.75 ,.0001 24.96 6 5.78 24.99 6 6.56 22.75 6 5.65 23.45 6 5.81 .062
ADCS-CGIC 3.62 6 1.01 3.62 6 1.05 3.93 6 0.85 .028 3.38 6 1.19 3.38 6 1.22 3.58 6 1.07 3.62 6 1.18 .45
Secondary outcomes
MMSE 1.85 6 1.29 1.81 6 1.55 0.37 6 2.53 ,.0001 3.26 6 2.31 3.33 6 2.43 2.35 6 2.63 2.09 6 1.52 .0028
CDR 21.05 6 0.56 21.06 6 0.55 21.13 6 0.51 .020 20.88 6 0.50 20.89 6 0.55 20.90 6 0.48 20.89 6 0.57 .75
CDR-SB 20.85 6 1.15 20.77 6 1.17 20.28 6 0.96 .00040 21.46 6 1.44 21.39 6 1.21 20.98 6 1.33 20.94 6 1.22 .041
ADCS-ADLs 4.18 6 4.79 4.01 6 5.11 1.80 6 5.11 .00080 7.40 6 5.10 7.41 6 5.31 5.78 6 5.60 5.47 6 5.03 .061
CLOX 1.00 6 1.87 1.01 6 2.10 0.02 6 2.01 .00030 1.70 6 2.44 1.72 6 2.31 0.96 6 2.02 1.09 6 2.71 .15
C-EXIT25 22.00 6 2.94 21.83 6 2.94 20.33 6 2.85 ,.0001 23.13 6 3.72 23.19 6 3.41 21.96 6 2.91 22.00 6 3.15 .052
NPI 20.82 6 2.46 20.94 6 2.63 20.43 6 2.87 .35 21.37 6 3.70 21.37 6 3.15 21.29 6 3.23 20.87 6 3.31 .84
Abbreviations: SD, standard deviation; VaDAS-cog, Vascular Dementia Assessment Scale–Cognitive subscale; ADCS-CGIC, Alzheimer’s Disease Cooper-
ative Study–Clinical Global Impression of Change; MMSE, Mini–Mental State Examination; CLOX, clock drawing task; C-EXIT25, Chinese version of the
executive interview; CDR, Clinical Dementia Rating; CDR-SB, the sum of boxes of the CDR; ADCS-ADLs, Alzheimer’s Disease cooperative study activities of
daily living; NPI, Neuropsychiatric Inventory; mITT, modified intent to treat.
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Table 3
Patients experiencing adverse events at weeks 26 and 52 in the SS population*
Event
Week 26 Week 52
Group A
(n 5 109)
Group B
(n 5 108)
Group C
(n 5 108) P value
Group A
(n 5 109)
Group B
(n 5 108)
Group C1
(n 5 53)
Group C2
(n 5 55) P value
AEs, number of patients experiencing event (%) 91 (83.5) 101 (93.5) 95 (88.0) .066 81 (74.3) 80 (74.1) 44 (80.0) 42 (79.3) .78
AEs occurring in at least 10 patients in either treatment group, n (%)
Increased triglyceride level 22 (20.2) 23 (21.3) 29 (26.9) .47 Increased triglyceride level 18 (16.5) 11 (10.2) 11 (20.0) 5 (9.4) .22
Increased blood glucose 24 (22.0) 23 (21.3) 27 (25.0) .82 Decreased high-density lipoprotein 14 (12.8) 12 (11.1) 11 (20.0) 3 (5.7) .16
Increased low-density lipoprotein 18 (16.5) 24 (22.2) 29 (26.9) .18 Increased blood glucose 16 (14.7) 12 (11.1) 6 (10.9) 5 (9.4) .79
Increased total cholesterol level 20 (18.4) 20 (18.5) 23 (21.3) .85 Increased total cholesterol level 9 (8.3) 12 (11.1) 7 (12.7) 7 (13.2) .69
Decreased high-density lipoprotein 17 (15.6) 12 (11.1) 11 (10.2) .46 Urinary leukocyte positive 10 (9.2) 10 (9.3) 6 (10.9) 8 (15.1) .66
Urinary leukocyte positive 13 (11.9) 10 (9.3) 6 (5.6) .27 Increased low-density lipoprotein 11 (10.1) 11 (10.2) 8 (14.6) 3 (5.7) .51
Increased blood uric acid 4 (3.7) 11 (10.2) 7 (6.5) .15
Possibly drug-related AEs, n (%)
Mild gastrointestinal intolerance 1 (0.9) 1 (0.9) 2 (1.9) .85 Mild gastrointestinal intolerance 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Abnormal alanine aminotransferase 4 (3.7) 0 (0.0) 2 (1.9) .17 Abnormal alanine aminotransferase 2 (1.83) 1 (0.9) 0 (0.0) 0 (0.0) .89
Abnormal aspartate aminotransferase 2 (1.83) 0 (0.0) 0 (0.0) .33 Abnormal aspartate aminotransferase 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Increased thrombin time 4 (3.7) 1 (0.9) 1 (0.9) .38 Increased thrombin time 4 (3.7) 2 (1.9) 1 (1.8) 2 (3.8) .77
Dreaminess 1 (0.9) 1 (0.9) 3 (2.8) .54 Dreaminess 0 (0.0) 2 (1.9) 2 (3.6) 2 (3.8) .11
Drug-related AEs resulting in treatment
discontinuation, n (%)
0 (0.0) 0 (0.0) 0 (0.0) 1.0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Any SAEs, n (%)
Acute cerebral infarction 1 (0.9) 0 (0.0) 1 (0.9) Acute cerebral infarction 2 (1.8) 0 (0.0) 1 (1.8) 0 (0.0)
Chronic bronchitis 0 (0.0) 1 (0.9) 0 (0.0) Small cell carcinoma of lung 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0)
Acute coronary syndromes 1 (0.9) 0 (0.0) 0 (0.0)
Abbreviations: AEs, adverse events, SAEs, serious adverse events; SS, safety set.
*There is no significant difference among the groups.
J.
Jia
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
:
T
ra
n
sla
tio
n
a
l
R
esea
rch
&
C
lin
ica
l
In
terven
tio
n
s
4
(2
0
1
8
)
1
0
8
-1
1
7
1
1
5
with multiple targets might be a good choice for the develop-
ment of anti-VaD drugs in the future.
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RESEARCH IN CONTEXT
1. Systematic review: We searched PubMed and clini-
caltrials.gov on February 29, 2017, for vascular de-
mentia (VaD) trials published in English journals
since January 1, 1990, using the search terms
“vascular dementia,” “clinical trial,” “compound
Chinese medicine,” and “SaiLuoTong/SLT” in any
field. However, we did not find any clinical trials
related to SaiLuoTong (SLT).
2. Interpretation: Our findings suggest that SLT had
larger effect sizes than seen previously for VaD. As
SLT is a compound Chinese medicine that contains
several active ingredients, from its components of
Ginkgo biloba, ginsenosides, and saffron, we specu-
lated that SLT might have multiple targets for treating
VaD. This forms a basis for better explaining the effec-
tiveness of SLT compared to single targets for VaD, as
published previously. Our study shows that a com-
pound Chinese medicine can be used to treat VaD.
3. Future directions: Another trial with a longer dura-
tion, larger sample size, and more markers of VaD
progression are warranted.
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